EU Cross border clinical trials
Access to cross-border clinical trials is crucial for providing cancer patients with enhanced access to innovative treatments, which can significantly improve treatment outcomes and, in some cases, be a matter of life or death. However, there is currently no EU-wide legal framework defining the conditions for accessing these trials across national borders and clinical trials are not equally available in all EU Member States, leading to large disparities across Europe.
CPE call for the development of an EU framework for cross-border clinical trials to achieve equity and ensure that all cancer patients, regardless of their location, can benefit from advancements in treatments.
CPE is a member of EU-X-CT, a multi-stakeholder initiative led by EFGCP and EFPIA, aimed at systematically collecting information on the barriers to cross-border participation in clinical trials from across Europe and developing recommendations for enabling better access. Click on the link to learn more about EU-X-CT.
Related News
At Cancer Patients Europe our vision is to reduce the burden of cancer on patients and survivors, their carers, the healthcare system and society as a whole. We achieve this by giving patients voice in policies that drive prevention, high quality cancer care, treatment and survivorship in Europe.
Our policy work includes anticipating, providing advice and contributing to the formulation of relevant legislative proposals taking place at the European level. Our activities on policy include the publication of Calls to Action, position papers, input on consultations by the European Commission, the European Medicines Agency and direct engagement with policymakers.
Learn more about our policy work as we continue to push for a brighter future for the cancer community.